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Protein N-myristoylation is a lipidic modiﬁcation which refers to the covalent attachment of myristate, a 14-carbon saturated fatty
acid, to the N-terminal glycine residue of a number of mammalian, viral, and fungal proteins. In this paper, we have cloned the
gene coding for myristoyl-CoA:protein N-myristoyltransferase (NMT) from Bos tarus brain. The open reading frame codes for
a 410-amino-acid protein and overexpressed in Escherichia coli. Kinetic studies suggested that bovine brain NMT2 and human
NMT1 show signiﬁcant diﬀerences in their peptide substrate speciﬁcities. The metal ion Ca
2+ had stimulatory eﬀects on NMT2
activity while Mn
2+ and Zn
2+ inhibited the enzyme activity. In addition, NMT2 activity was inhibited by various organic solvents
and other detergents while NMT1 had a stimulatory eﬀect. Biochemical characterization suggested that both forms of NMT have
unique characteristics. Further analysis towards functional role NMT2 will lead the development of therapeutic target for the
progression of various diseases such as cancer, cardiovascular diseases, and neurodegenerative diseases.
Copyright © 2009 Ponniah Selvakumar et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
Protein N-myristoylation is a lipidic modiﬁcation which
refers to the covalent attachment of myristate, a 14-carbon
saturated fatty acid, to the N-terminal glycine residue of a
number of mammalian, viral, and fungal proteins [1–8]. In
general, N-myristoylation is an irreversible cotranslational
protein modiﬁcation which occurs after removal of the
initiatormethionineresiduebymethionineaminopeptidases
[7, 8]. However, there is an instance where N-myristoylation
occurs posttranslationally as is the case of proapoptotic
protein BID where it is cleaved by caspase 8, to reveal
a myristoylation motif [9], at aspartate 60 and aspartate
75 to generate truncated BID forms that facilitate release
of mitochondrial cyctochrome c [10]. N-myristoylation
ensures the proper functioning and intracellular traﬃcking
of proteins. Many proteins involved in a wide variety of
signal cascades; cellular transformations and oncogenesis are
myristoylated [1–8].
Myristoylation of proteins is catalyzed by the ubiq-
uitously distributed eukaryotic enzymes N-myristoyltrans-
ferase (NMT) which is a member of the GNAT superfamily
of proteins [1–8]. Despite recent advances in the protein
myristoylationﬁeld,thespeciﬁcitiesofthevariousNMTsand
the diﬀerences in species speciﬁcity among various putative
isoenzymes are yet to be undertaken. Biochemical evidence
has indicated the presence of several distinct NMTs in vivo,
often varying in either apparent molecular weight and/or
subcellular distribution. We provided the ﬁrst evidence for
theexistenceofmultipleformsofbovinebrainNMT[11].In
addition,McIlhinneyetal.[12]identiﬁedtwoformsofNMT
inbovinebraincortex.Subsequently,GloverandFelsted[13]
showed that bovine brain exists as a heterogeneous mixture
of NMT subunits. Two types of NMT, NMT1, and NMT2,
were identiﬁed. NMT1 was extensively studied from various
sources [14, 15]. The biochemical characterization of NMT2
is yet to be explored. Comparisons between the NMT1 and
NMT2 proteins revealed reduced levels of sequence identity
(76-77%), indicating that NMT1 and NMT2 comprise two
distinct families of NMTs [14]. The speciﬁc inhibition or
regulation of either NMT in vivo may in turn allow for
the selective control of particular myristoylation-dependent
cellular functions.2 Journal of Biomedicine and Biotechnology
We have reported that NMT activity and expression were
elevated in rat [16] and human colon carcinomas [17]. In
addition, we reported high expressions of both NMT1 and
NMT2 in human brain tumors [18] and human colorectal
cancer [18]. Also we have also demonstrated the interaction
of various signaling molecules such as m-calpain, caspase-3,
p53, and Bcl2 with NMT1 and NMT2 in human colorectal
cancer [19]. It is clearly established that both forms of
NMT have a unique functional role in the progression of
various diseases such as cancer, cardiovascular diseases, and
neurodegenerative diseases [20, 21]. The present study was
undertaken to examine the biochemical characterization of
bovine brain NMT2 to distinguish from NMT1.
In this paper, we report the molecular cloning, expres-
sion, and biochemical characterizations of NMT2 from B.
tarus brain. Kinetic studies suggested that bovine brain
NMT2 and human NMT1 show signiﬁcant diﬀerences in
their peptide substrate speciﬁcities. The metal ions Ca2+,
Mn2+,a n dZ n 2+ inhibited the enzyme activity. In addition,
NMT2 activity was inhibited by various organic solvents and
other detergents while NMT1 had a stimulatory eﬀect.
2.MaterialsandMethods
2.1. Materials. [9,10-3H]myristic acid was purchased from
Perkin-Elmer, Canada. Pseudomonas acyl-CoA synthetase,
and coenzyme A were obtained from Sigma. pQE-9 was pur-
chased from Qiagen, Canada. Restriction endonucleases and
DNA modifying enzymes were purchased from Amersham
Pharmacia Biotech. Ligation Pack was purchased from New
England Biolabs, USA. Anti-NMT2 was obtained from BD
biosciences, Canada. General laboratory chemicals were of
analytical grade. The following peptides were synthesized by
theAlbertaPeptideSynthesis,Alberta,Canada.Gly-Asn-Ala-
Ala-Ala-Ala-Lys-Lys-Arg-Arg (based on the NH2-terminal
sequence of the type I1 catalytic subunit of cAMP-dependent
protein kinase), Gly-Ser-Ser-Lys-Ser-Lys-Pro-Lys-Arg (the
NH2-terminal sequence of pp60Src), Gly-Asn-Ala-Ser-Ser-
Ile-Lys-Lys-Lys (the NH2-terminal sequence of the M2 gene
segment of reovirus type 3, and Gly-Ala-Gln-Phe-Ser-Lys-
Thr-Ala-Arg-Arg (the NH2-terminal sequence of myristoy-
lated alanine-rich C kinase substrate (MARCKS)).
2.2. Molecular Cloning, Expression, and Puriﬁcationof Recom-
binant NMT2. General cloning techniques were carried out
essentially as described by Sambrook et al. [22]. Total RNA
was prepared using the RNeasy Mini Kit (Qiagen, Hilden,
Germany). PCR with degenerate oligonucleotides was used
to amplify a DNA fragment encoding the NMT2. Sense and
antisense oligonucleotide primers were designed based on
retina NMT2 (AF222687). The sense oligonucleotide (5 -
GGA TCC ATG GCG GAG GAC AGC GAG TC-3 , BamHI
restriction site) and antisense oligonucleotide (5 -AAG CTT
CTA CTG TAA TAC GAG TCC AAC CTT TTC AGA C-3 ,
HindIII restriction site). PCR was performed with the total
RNA as a template in a GeneAmp PCR System 2400 (Applied
Biosystems) for 35 cycles (each consisting of denaturation at
94◦C for 30 seconds, annealing at 51◦C for 30 seconds, and
extension at 72◦C for 1 minute) using One Step RT-PCR kit
(Qiagen).AmpliﬁedPCRproductswereclonedintotheZero
Blunt Topo vector (Invitrogen), and their DNA sequences
were determined and designated as pZeroBlunt NMT2. The
vector pQE9 was treated with BamHI and HindIII. An insert
NMT2 gene was prepared by digestion of clone pZeroBlunt
NMT2 and puriﬁed by agarose gel electrophoresis. The
insert was ligated with vector and used to transform E. coli
M13. The recombinant plasmid was puriﬁed and designated
pQE9-NMT2.
E. coli M13 cells transformed with pQE-9 were grown
at 37◦C in Luria-Bertani medium containing 100μg/mL
ampicillin until the optical density at 600nm reached about
0.5. Then isopropylthio-β-galactopyranoside (IPTG) was
added to the culture at the ﬁnal concentration of 1mM,
and cultivation was continued for an additional 5 hours at
37◦C. Bacterial cells were harvested by centrifugation and
resuspended in 1mL of lysis buﬀer (50mM Tris-HCl, pH
8.0, 300mM NaCl, 10mM imidozol). They were then lysed
by addition of lysozyme to a ﬁnal concentration of 1mg/mL
on ice for 30 minutes followed by sonication in a Sonics and
Materials VibraCell Sonicator, for 6 × 10s bursts. The lysate
was cleared by centrifugation (10000g, 30 minutes at 4◦C)
a n dl o a d e do nt oa nN i - N T Aa ﬃnity column, equilibrated
with lysis buﬀer. The column was washed extensively with
wash buﬀer (50mM Tris-HCl, pH 8.0, 300mM NaCl and
20mM imidozol), and then the bound protein was eluted
from the column using elution buﬀer (50mM Tris-HCl,
pH 8.0, 300mM NaCl, and 250mM imidozol). The purity
of brain NMT2 was analyzed by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) and the
puriﬁed fractions were pooled and stored at −80◦Cf o r
further analysis.
2.3. NMT Assay and Kinetics. NMT activity was measured as
previously described [23]. For the standard enzyme assays,
the reaction mixture contained 0.4μM[ 3H]myristoyl-CoA,
50mM Tris-HCl, pH 7.8, 0.5mM EGTA, 0.1% Triton X-
100, 500μM synthetic peptide, and puriﬁed NMT2 in a total
volume of 25μL. The reaction was initiated by the addition
of radiolabeled [3H]myristoyl-CoA and incubated at 30◦C
for 10–30 minutes. The reaction was terminated by spotting
aliquots of incubation mixture onto P81 phosphocellulose
paper discs and drying them under a stream of warm
air. The P81 phosphocellulose paper discs were washed in
three changes of 40mM Tris-HCl, pH 8.0, for 90 minutes.
The radioactivity was quantiﬁed in 7.5mL of Beckman
Ready Safe Liquid Scintillation mixture using a Beckman
Liquid Scintillation Counter. One unit of NMT activity was
expressed as 1pmol of myristoyl-peptide formed per minute
per mg protein. Kinetics studies were carried out by varying
the enzyme and peptide concentrations.
2.4. Eﬀect of Metal Ions, Organic Solvents, Detergents on
NMT2. To determine the eﬀect of metal ions on NMT2
activity, we incubated the puriﬁed NMT2 with various
concentrations(0–5mM)ofCa2+,Mn 2+,Mg 2+,Fe 2+,orZn 2+
in the reaction mixture and the eﬀect of NMT2 activity wasJournal of Biomedicine and Biotechnology 3
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Figure 1: Comparison of the amino acid sequences of diﬀerent species of NMT2. The multiple sequence alignment was generated using
the ClustralW program. The conservation is represented by the following colors: primary (red, 90–100%), secondary (green, 70–89%),
tertiary (light green, 50–69%), and quaternary (yellow, 30–49%). The deduced amino acid sequence of bovine brain NMT2 was aligned
with B. taurus retina, AAA73914; H. sapiens, NP005337; M. musculus, AAC84169; R. norvegicus, CAA52328; A. thaliana; AAC23421; NMT1
B. taurus, BC109533.4 Journal of Biomedicine and Biotechnology
assayed as described above. The NMT2 activity was carried
outinthepresenceofSDS(0–10mM),ethanol(0–25%),and
acetonitrile (0–25%) using cAMP-dependent protein kinase
as peptide substrate.
2.5. SDS-Polyacrylamide Gel Electrophoresis and Western Blot
Analysis. Thirty micrograms of total cellular protein were
resolved on a 10% SDS-PAGE according to the procedure
described by Laemmli [24]. Gel transfer to nitrocellulose
membrane and blocking were performed using standard
procedures [25]. The blot was incubated with the NMT2
antibodiesat1 : 1000,washedandprobedwithanantimouse
IgG horseradish peroxidase conjugate diluted 1 : 2000.
Membranes were then incubated in chemiluminescence
reagents and exposed to Kodak X-OMAT Blue XB-1 ﬁlm for
detection. The blot was reprobed with β-actin after stripping
for 30 minutes in 62.4mM Tris-HCl, pH 6.8, and 2% SDS
containing 10mM β-mercaptoethanol at 60◦C.
2.6. Other Methods. Protein concentration was measured by
the method of Bradford [26] using bovine serum albumin as
the standard. The nucleotide and amino acid sequences were
evaluated using the MacVector computer program.
3. Results andDiscussion
N-Myristoylation of proteins is a cotranslational event [1–8],
and it appears to play an important role in mediating speciﬁc
protein-protein orprotein-lipid interactions, ligand-induced
protein conformational changes, and subcellular targeting
[1–8]. The enzyme responsible for this modiﬁcation, NMT,
has been extensively studied in yeast and mammalian cells
because NMT is a potential target for anticancer, antiviral,
antifungal, and antineoplastic therapy [1–3]. Various reports
including our laboratory demonstrated that both forms of
NMT have a unique functional role in the progression of
various diseases such as cancer, cardiovascular diseases, neu-
rodegenerative diseases. The present study was undertaken
to examine the biochemical characterization of bovine brain
NMT2 to distinguish from NMT1. In addition, very little
information is available about NMT2 in myristoylation.
3.1. Cloning of Bovine Brain NMT2. In order to clone
NMT2 from bovine brain, total RNA from bovine brain
was reverse transcribed to cDNA using One-Step RT-PCR
Kit. The degenerate primers for NMT2 were designed based
on the DNA sequences of bovine retina NMT2 [27]. These
primers ampliﬁed an expected PCR product of ∼1.5kb.
The ampliﬁed cDNA was cloned into pZeroBlunt vector
and the complete nucleotide sequence was determined.
The single long open reading frame (1494bp) of bovine
brain tissue NMT2 speciﬁes a protein of 498 amino acids.
Sequence analysis revealed that bovine brain NMT2 has 99%
homologytoretinaNMT2ataminoacidlevel.Toanalyzethe
similarity of bovine brain NMT2 with other NMT2 family
proteins, we compared the amino acid sequence of various
species of NMT2 using ClustralW program. The bovine
brain NMT2 exhibited 100% similarity with Homo sapiens,
B. taurus brain NMT2
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Figure 2: Molecular phylogenetic tree of the amino acid sequences
of NMT2s from various species. The tree was constructed by the
neighbor joining method, based on sequence information.
91.9%withRattusnorvegicus,86.4%withMus musculus,and
51.6% with Arabidopsis thaliana (Figure 1) .Ah i g hd e g r e e
of sequence conservation was observed in NH2-terminal
sequence of diﬀerent species. Within the coding region there
is 92.4% identity with the human NMT1 at the nucleotide
level [2]. The bovine NMT1 exhibited 83.2% similarity with
bovine brain, retina and H. sapiens NMT2, 79.4% with
M. musculus NMT2, 77.9% with R. norvegicus NMT2, and
52.5% with A. thaliana NMT2.
3.2. Phylogenetic Analysis of NMT2. Phylogenetic analysis
of NMT2 family reveals that it can be grouped into three
major families (Figure 2). Group one family is composed
of proteins from A. thaliana, the second family consists
of R. norvegicus, H. sapiens,a n dB. Taurus, and the third
family consists of M. musculus. The second family further
subgrouped into R. norvegicus, H. sapiens,a n dB. taurus.
The phylogenetic tree suggested that B. taurus belongs to the
second group.
3.3. Expression and Puriﬁcation of Bovine Brain NMT2.
Subsequently, the cDNA of NMT2 was subcloned in to
the expression vector pQE9 and transformed in to E. coli
M13 (pREP4). For the puriﬁcation of recombinant brain
NMT2, the crude cell lysate was applied to Ni-NTA Agarose
column and the bound His6-NMT2 was eluted as described
in the experimental procedures. This single step puriﬁcation
was suﬃcient to produce highly puriﬁed recombinant brain
NMT2 as judged by coomassie staining of samples resolved
by SDS-PAGE (Figure 3(a)). The molecular mass of puri-
ﬁed brain NMT2 was 50kDa. Furthermore, a monoclonal
antibody raised against brain NMT2 was immunoreactive
towards the recombinant brain NMT2 protein (Figure 3(b)).
This is in general agreement with previous studies of
other NMTs that gave molecular mass of 50–60kDa for
monomeric human [29, 30], 50kDa for bovine spleen [31]
and cardiac muscle [20], 55kDa for yeast [32], 53kDa
for Candida albicans [33], and 46kDa for Drosophila [34].
However, NMTs from murine leukemia cell line L1210 [35]
and bovine brain [13] have been demonstrated to exist in
multiple isoforms.Journal of Biomedicine and Biotechnology 5
Table 1: Peptide substrate speciﬁcity of the recombinant bovine brain NMT2. The recombinant bovine brain NMT2 assay was measured in
the presence of varying concentrations of various peptide substrates (0–1000μM). The reaction was carried out as described in Section 2.
The data shown represent the mean of three replicates. The human NMT1 values were adopted from [28]. Peptides derived from known
mammalian N-Myristoyl proteins.
Peptide sequence Km Vmax
Bovine NMT2 Human NMT1 Bovine NMT2 Human NMT1
GSSKSKPKR
a 5.3 44 88 120
GNAAAAKKRR
b 44 115 48 95
GNASSIKKK
c 8.5 136 72 66.8
aPeptide derived from NH2-terminal sequence of pp60src.
bPeptide derived from NH2-terminal sequence of cAMP-dependent protein kinase.
cPeptide derived from NH2-terminal sequence of M2 gene segment of reovirus type 3.
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Figure 3: SDS-PAGE and Western blot analysis of bovine brain
NMT2. Thirty microgram of proteins was loaded onto (a) SDS-
PAGE; lane 1, crude cell lysate; lane 2, puriﬁed E. coli expressed
bovine brain NMT2. (b) Puriﬁed E. coli expressed bovine brain
NMT2 (thirty microgram) immunoblotted with monoclonal anti-
NMT2 (1:1000 dilution) as described in Section 2.
3.4.KineticStudiesofNMT2. Comparativestudiesofpeptide
substrate speciﬁcities between bovine brain NMT2 and
human NMT1 enzymes revealed signiﬁcant diﬀerences in
their respective catalytic eﬃciencies (the details are sum-
marized in Table 1). The results suggested that bovine
brain NMT2 had lower Km values towards pp60src peptide
sequence than other peptide sequence. The peptide derived
from cAMP-dependent protein kinase exhibited a 2.6-fold
lower Km value than human NMT1. Interestingly, bovine
brain NMT2 showed a 16-fold lower Km toward peptide
derived from M2 gene while 8.3 folds lower toward peptide
derived from pp60src. Taken together, the results clearly
suggest that bovine brain NMT2 and human NMT1 show
signiﬁcant diﬀerences in their peptide substrate speciﬁci-
ties.
3.5. Eﬀect of Metal Ions. We examined the eﬀect of vari-
o u sd i v a l e n tc a t i o n so nN M T 2 .T h em e t a li o nC a 2+ had
stimulatory eﬀects on NMT2 activity at lower concentra-
tion (0.25mM) while higher concentration showed inhi-
bition of enzyme activity and 40% of the NMT2 enzyme
activity inhibited at 5mM concentration (Figure 4(a)).
The myristoylated MARCKS, a major in vivo substrate
of protein kinase C, interacts with plasma membranes
in a phosphorylation-, myristoylation-, and calmodulin-
dependent manner [28]. Therefore, we interested to examine
the eﬀect of calmodulin (CaM) on NMT2 activity and
observed that there was no signiﬁcant eﬀect of CaM on
NMT2 activity (Figure 4(b)). We observed a 50% loss of
enzyme activity by Mn2+ at 5mM concentration. Interest-
ingly, Zn2+ showed maximum inhibition compared to other
divalent cations tested and 80% of the enzyme activity was
abolished at 5mM concentration (Figures 4(c) and 4(e)).
ThemetalionsMg2+ hadnegligibleeﬀectsonNMT2activity,
indicating that the enzyme does not require these divalent
cations for its activity (Figure 4(d)). The metal ions Mg2+,
Ca2+,a n dM n 2+ had negligible eﬀects on Arabidopsis NMT1
activity, indicating that the enzyme does not require these
divalent cations for its activity [36].
3.6. Eﬀect of SDS on NMT2. Another interesting ﬁnding
observed in this study was that NMT2 was found to be
activated 2.5 folds with SDS. The optimum concentration
wasfoundtobe3.0mM(Figure 5).Theseresultssuggestthat
a mild concentration of detergent could open the structure
of NMT2, thereby allowing NMT2 to become highly active.
However at higher concentrations of SDS, NMT2 activity
was totally inactivated, suggesting that there is an optimum
level of structural changes in NMT2. Results also suggest
that some thiol group(s) in NMT2 could be masked inside
the protein. In the presence of SDS, these thiol group(s)
could be unmasked and thereby reactive. Human NMT1
was found to be activated several folds with SDS and
optimum concentration was found to be 1.73mM [37]. It
has been reported that in aldolase, one thiol per subunit
reacts readily, but an additional three groups react if a small
amount of detergent is added [38]. Human NMT has been
shown to be susceptible towards N-5,5  dithiobis (2-nitro-
benzoic acid) (DTNB) and iodoacetamide, suggesting the
implication of cysteine requirement for the enzyme catalysis
[39]. Comparison of four yeasts and one human NMT
protein sequences revealed that 2 cysteine residues at amino
acids 169 and 214 in human NMT and 172 and 217 in
yeast NMT were highly conserved [40, 41]. Bovine spleen
NMT has been shown to be activated several folds with SDS
[42].6 Journal of Biomedicine and Biotechnology
N
M
T
2
a
c
t
i
v
i
t
y
(
%
)
0
20
40
60
80
100
120
140
Ca2+ (mM)
012345
(a)
N
M
T
2
a
c
t
i
v
i
t
y
(
%
)
0
60
70
80
90
100
110
CaM (μg/assay)
012345
(b)
N
M
T
2
a
c
t
i
v
i
t
y
(
%
)
0
20
40
60
80
100
120
Mn2+ (mM)
012345
(c)
N
M
T
2
a
c
t
i
v
i
t
y
(
%
)
0
20
40
60
80
100
120
Mg2+ (mM)
012345
(d)
N
M
T
2
a
c
t
i
v
i
t
y
(
%
)
0
20
40
60
80
100
120
Zn2+ (mM)
012345
(e)
Figure 4: Eﬀect of metal ions on bovine brain NMT2 activity. Bovine brain NMT2 (1.0μg/assay) activity was determined in the presence
of carrying concentrations of (a) Ca2+,( b )C a M ,( c )M n 2+,( d )M g 2+, and (e) Zn2+ using cAMP-dependent protein kinase derived peptide
substrate (1.0mM). The reactions were initiated by the addition of 0.27μM[3H] myristoyl CoA and incubated at 30◦Cf o r3 0m i n u t e s .T h e
data presented are representative of at least three separate experiments.Journal of Biomedicine and Biotechnology 7
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Figure 5: Eﬀect of SDS on bovine brain NMT2 activity. Bovine
brain NMT2 (1.0μg/assay) activity was determined in the pres-
ence of carrying concentrations of SDS (0–10mM) using cAMP-
dependent protein kinase derived peptide substrate (1.0mM). The
reactions were initiated by the addition of 0.27μM[3H] myristoyl
CoA and incubated at 30◦C for 30 minutes. The data presented are
representative of at least three separate experiments.
3.7. Eﬀect of Organic Solvents on NMT2. We investigated the
eﬀect of ethanol and acetonitrile on NMT2 and we observed
that the NMT2 activity was inhibited by ethanol and
acetonitrileat the concentration of 15 and 10%, respectively,
(Figure 6). Like bovine spleen NMT [43], human NMT
was also found to be activated several folds with organic
solvents such as ethanol and acetonitrile [43]. It has been
reported that ethanol enhances the stimulatory eﬀect of
insulin and insulin-like growth factor-1 on DNA synthesis
in NIH 3T3 ﬁbroblasts [44]. It has also demonstrated
that ethanol enhances the expression of cell surface class
I major histocompatibility complex antigens in a variety
of cell lines [45]. Also reported is that ethanol activates
nonactivated phosphorylase kinase at pH 6.8, similar to
the activation achieved by phosphorylation at two speciﬁc
sites on phosphorylase kinase by cAMP dependent protein
kinase [46]. It appears from these studies that ethanol
could act as a second messenger in the signal transduction
pathway to further propagates the signals such as substrate
expression, substrate accessibility, or regulation of NMT
activity.
Inconclusion,wehaveprovidedabiochemicalcharacter-
ization of bovine brain NMT2. Bovine brain NMT2 diﬀers
from human NMT1 with respect to its peptide substrate
preference. The metal ion Ca2+,M n 2+,a n dZ n 2+ inhibited
the NMT2 enzyme activity. In addition, NMT2 activity was
inhibited by various organic solvents and other detergents
while NMT1 had a stimulatory eﬀect. The availability of
NMT2 gene, recombinant NMT2 protein, antibody, and
information regarding NMT2 protein properties will facili-
tate further investigations to determine the role(s) of protein
N-myristoylation as well as to deﬁne NMT protein targets
in various chronic diseases such as cancer, cardiovascular
diseases, and neurological diseases.
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Figure 6: Eﬀect of ethanol (a) and acetonitrile (b) on bovine brain
NMT2. Bovine brain NMT2 (1.0μg/assay) activity was determined
in the presence of carrying concentrations (0–25%) of ethanol and
acetonitril using cAMP-dependent protein kinase derived peptide
substrate (1.0mM). The reactions were initiated by the addition of
0.27μM[3H] myristoyl CoA and incubated at 30◦Cf o r3 0m i n u t e s .
The data presented are representative of at least three separate
experiments.
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